3Hafian H,Venteo L,Sukhanova A,et al.Immunohistochemical study of DNA topoisomerase Ⅰ,DNA topoisomerase Ⅱ alpha,P53 and Ki-67 in oral preneoplastic lesions and oral squamus cell carcinomas[J].Hum Pathol,2004 ;35 (6):745 -6.
5Gotlieb WH,Goldberg I,Weise B,et al.TopoisomeraseⅡ immunostaining as a prognostic marker for survival in ovarian cancer[J].Genecol Oncol,2001 ;82(1):99-104.
5Huesker M, Folmer Y, Schneider M, et al. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes[J]. Hepatology,2002;36(4 Pt 1):874.
6Gregory F, Sullivan B, Jin M Y, et al. Modulation of MDR/MRP by wild-type and mutant p53. J Clin Invest, 2001;107(5):645.
7Oudards S, Levalois C, Andrieu JM, et al. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome[J]. Anticancer Res,2002;22(1A):121.
8Tsuruo T. Molecular cancer therapeutics: recent progress and targets in drug resistance[J]. Intern Med,2003;42(3):237.
9Kellner U, Hutchinson L, Seidel A, et al. Decreased drug accumulation in mitoxantrone resistant gastric carcinoma cell line in the absence of P-glycoprotein[J]. Int J Cancer,1997;71:817.
10Fournier B,Hooper DC.Effects of mutations in gral of topoisomerase П form staphglococcus aureus on quinolone and coumarin activity[J].Antimicrob Agents Chemother,1998,4(8):2109.
